Both monoclonal and polyclonal anti-TLR4 antibodies are currently under investigation as therapeutic agents in the prevention of septic shock induced by LPS [15], and a number of anti-TLR4 antibodies are currently in clinical trials to improve test their effectiveness in diseases including rheumatoid arthritis [16]. The gene discussed is TLR4; the disease is rheumatoid arthritis.